argenx agreed to acquire Forte Biosciences for $2.2 billion, $77 per share in cash, with no milestone tail. The lead asset is FB102, a first-in-class anti-CD122 antibody with Phase 1b proof of concept in vitiligo and coeliac disease, and stated potential in alopecia areata and other autoimmune conditions. The price is an 86 percent premium to Forte’s volume-weighted average since it reported positive vitiligo data on 9 July.

No earnout, no contingent value right, no milestones. The buyer took the risk outright.

A structure with nothing contingent in it is a statement. Milestones exist to move risk back onto the seller when a buyer is unsure, and argenx declined the option on an asset whose human evidence is a Phase 1b readout three weeks old. Note where the money went. FB102 is aimed at vitiligo and alopecia areata, the same two indications in which AbbVie won European approval for RINVOQ this week. One company is launching into those diseases, another just paid $2.2 billion for the right to follow. Autoimmune dermatology stopped being a quiet corner some time ago and the market has now priced it accordingly.

J&J committed $785 million on signing, including a $465 million equity investment through JJDC, plus $140 million in development milestones and an exclusive option to acquire Sail Biomedicines for a further $2.58 billion. Sail, a Flagship Pioneering company, is developing in vivo CAR-T for immune-mediated disease. Its lead candidate SAIL-0839 is preclinical and its target diseases are undisclosed.

Two immunology deals in one week: 100 percent upfront for Phase 1b, 22 percent for preclinical. That gradient is the whole discipline.

Read the two together and you have the conviction curve drawn in a single week, in a single therapy area. An asset with human data commands everything on signing. A platform that has never been in a patient commands a fifth, and the buyer keeps the right to walk. Neither is a better deal than the other. They are correctly priced for what is known, which is what an upfront ratio is for.

Beyond the two headline transactions, Vertex licensed AbCellera’s multispecific T-cell engager platform for autoimmune disease at $28 million upfront, and Caldera Therapeutics went public through a reverse merger to develop a bispecific antibody against IL-23p19 and TL1A in inflammatory bowel disease.

Antibody, cell therapy, T-cell engager, bispecific. One destination.

What is notable is not that immunology attracted capital, it does most weeks. It is that four different modalities were bought into the same destination inside five days, by acquirers with very different balance sheets. J&J is buying because its own immunology franchise shrank 3.7 percent last quarter as STELARA gave way to biosimilars. Everyone else is buying because that is what the next decade looks like, whether or not their current franchise is eroding yet.

Oak Hill Bio is reverse merging into a SPAC and will list on Nasdaq as OAKH, developing rugonersen, an antisense oligonucleotide designed to restore UBE3A activity in nerve cells. Caldera is reverse merging with Synlogic to reach the public market under CALD.

Two listings in a week, neither of them an IPO.

Reverse mergers are what companies use when they need public currency and the conventional route is closed or too slow. Two in five days is not a trend on its own, but it is worth logging against the financing pattern of the last several weeks, where a small number of large private placements have coexisted with almost no traditional listings. Capital is available. The public window is not, and companies are going through the side entrance to reach it.

MiMedx agreed to acquire Sanara MedTech for $350 million, taking CellerateRX surgical powder, the BIASURGE irrigation solution and an injectable bone adhesive. Elsewhere, Eisai licensed to CORE Biomedicine, Harbour BioMed partnered with Sinopharm, BioMarin took a licence from the n-Lorem Foundation, and roughly a dozen further transactions were announced without financial terms.

Thirteen deals with no numbers is not an absence of information. It is a category.

Undisclosed terms cluster where the amounts are small enough that neither party benefits from publishing them, or where the acquirer is private. Both are true here. The MiMedx transaction is the one worth watching, because it lands as CMS pressure on skin substitute reimbursement intensifies, and consolidating wound care products under one owner ahead of a payment reset is a defensible move or an expensive one depending entirely on where that reset lands.